ArticleBMC urology2022

Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma.

Kazuma Sugimoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.